{"id":2388,"date":"2026-02-18T15:10:06","date_gmt":"2026-02-18T14:10:06","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/new-final-data-immunotherapy-with-atezolizumab-does-not-provide-additional-benefit-in-recurrent-ovarian-cancer\/"},"modified":"2026-03-05T11:57:27","modified_gmt":"2026-03-05T10:57:27","slug":"new-final-data-immunotherapy-with-atezolizumab-does-not-provide-additional-benefit-in-recurrent-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/en\/new-final-data-immunotherapy-with-atezolizumab-does-not-provide-additional-benefit-in-recurrent-ovarian-cancer\/","title":{"rendered":"New final data: Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"2388\" class=\"elementor elementor-2388 elementor-2383\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e438c86 e-flex e-con-boxed e-con e-parent\" data-id=\"e438c86\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2cf51b7 elementor-widget elementor-widget-heading\" data-id=\"2cf51b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>New final data:<\/strong> Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-070f551 elementor-widget elementor-widget-text-editor\" data-id=\"070f551\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p data-start=\"321\" data-end=\"838\">The final results of the <strong data-start=\"368\" data-end=\"398\">AGO-OVAR 2.29 (ENGOT-ov34) <\/strong>study were published in December 2025.<\/p><p data-start=\"321\" data-end=\"838\">This large international phase III trial investigated whether the additional administration of the immunotherapy drug <strong data-start=\"471\" data-end=\"487\">atezolizumab<\/strong> together with <strong data-start=\"501\" data-end=\"516\">bevacizumab<\/strong> and non-platinum-based chemotherapy can prolong the survival of patients with <strong data-start=\"598\" data-end=\"632\">recurrent ovarian cancer<\/strong>.<br data-start=\"649\" data-end=\"652\">This form of cancer recurs even though platinum-based chemotherapy has already been given and is considered particularly difficult to treat.<\/p><p data-start=\"840\" data-end=\"1062\">A total of 574 patients were randomized in the study and received either the standard treatment (chemotherapy + bevacizumab + placebo) or atezolizumab in addition.<\/p><h3 data-start=\"1064\" data-end=\"1102\"><strong>What did the study show?<\/strong><\/h3><p data-start=\"1103\" data-end=\"1195\">\u27a1\ufe0f <strong data-start=\"1106\" data-end=\"1143\">No clear survival benefit<\/strong> was found with the addition of atezolizumab:<\/p><ul data-start=\"1196\" data-end=\"1809\"><li data-start=\"1196\" data-end=\"1504\"><p data-start=\"1198\" data-end=\"1504\">The median <strong data-start=\"1210\" data-end=\"1239\">overall survival (OS)<\/strong> was around <strong data-start=\"1270\" data-end=\"1286\">14.2 months<\/strong> with atezolizumab and <strong data-start=\"1317\" data-end=\"1333\">13.0 months<\/strong> in the control group &#8211; this difference was <strong data-start=\"1359\" data-end=\"1392\">not statistically significant<\/strong>, i.e. not clear enough to speak of a reliable advantage.<\/p><\/li><li data-start=\"1505\" data-end=\"1809\"><p data-start=\"1507\" data-end=\"1809\">The median <strong data-start=\"1519\" data-end=\"1556\">progression-free survival (PFS)<\/strong> &#8211; i.e. the time in which the tumor does not grow again &#8211; was practically the same with atezolizumab compared to <strong data-start=\"1665\" data-end=\"1680\">6.7 months<\/strong> in the control group and also without a statistically proven advantage.<\/p><\/li><\/ul><p data-start=\"1811\" data-end=\"2076\">\ud83d\udca1 This means that immunotherapy with atezolizumab did not lead to a clear improvement in disease control or prolongation of life when given in addition to bevacizumab and chemotherapy in this study.<\/p><h3 data-start=\"2078\" data-end=\"2125\"><strong data-start=\"2083\" data-end=\"2123\">What about side effects?<\/strong><\/h3><p data-start=\"2126\" data-end=\"2409\">Severe side effects (grade \u2265 3) occurred slightly more frequently in patients receiving atezolizumab (72% vs. 69%), but overall the safety profile was <strong data-start=\"2290\" data-end=\"2370\">comparable to that already known for the individual drugs<\/strong>.<\/p><h3 data-start=\"2411\" data-end=\"2476\"><strong data-start=\"2416\" data-end=\"2474\">Was a difference observed depending on PD-L1 status?<\/strong><\/h3><p data-start=\"2477\" data-end=\"2805\">The study also investigated whether patients with PD-L1-positive tumors (a possible indication of a better response to immunotherapy) benefit more from atezolizumab. This was not the case &#8211; the results were similar regardless of whether the tumor was PD-L1-positive or -negative. <br><br><\/p><p data-start=\"3203\" data-end=\"3462\"><strong data-start=\"3206\" data-end=\"3241\">Important contribution to research<\/strong><br data-start=\"3241\" data-end=\"3244\">Even if these particular results are negative, such large studies are important in order to understand exactly <strong data-start=\"3360\" data-end=\"3419\">which therapies really help in which situations<\/strong> &#8211; and where we still need new approaches.<\/p><p data-start=\"3464\" data-end=\"3827\">\ud83d\udca1 <strong data-start=\"3467\" data-end=\"3500\">Standards remain unchanged<\/strong><br data-start=\"3500\" data-end=\"3503\">For patients with platinum-resistant recurrence, the established treatment options, such as chemotherapy with bevacizumab or other effective combinations, currently remain the recommended standard. Immunotherapy such as atezolizumab is currently <strong data-start=\"3760\" data-end=\"3792\">not demonstrably more effective<\/strong> than standard treatment in this setting. <br><br><\/p><p><span style=\"color: #29b8ce;\"><strong>Source:<\/strong> <\/span><a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO-25-01210\" target=\"_blank\" rel=\"noopener\">Publication from ASCO<\/a> (the article is in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New final data: Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer The final results of the AGO-OVAR 2.29 (ENGOT-ov34) study were published in December 2025. This large international phase III trial investigated whether the additional administration of the immunotherapy drug atezolizumab together with bevacizumab and non-platinum-based chemotherapy can prolong the survival of [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":1497,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-2388","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=2388"}],"version-history":[{"count":6,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2388\/revisions"}],"predecessor-version":[{"id":2442,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/posts\/2388\/revisions\/2442"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media\/1497"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=2388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/categories?post=2388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/en\/wp-json\/wp\/v2\/tags?post=2388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}